Heron Therapeutics Files 8-K: Officer Changes & Exhibits
Ticker: HRTX · Form: 8-K · Filed: Apr 6, 2026 · CIK: 0000818033
Sentiment: neutral
Topics: officer-change, filing, exhibit
Related Tickers: HRTX
TL;DR
Heron Therapeutics (HRTX) filed an 8-K detailing officer changes and compensation. Keep an eye on leadership stability.
AI Summary
Heron Therapeutics, Inc. filed an 8-K on April 6, 2026, reporting on the departure of a director and the appointment of a new officer. The filing also includes details on compensatory arrangements for certain officers and financial statements/exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and provides updated financial and compensatory information, which could influence investor perception.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine changes and disclosures, not indicating immediate operational or financial distress.
Key Numbers
- 85085 — 8-K iXBRL Document Size (Size of the main 8-K filing document in bytes.)
- 161955 — EX-10.1 Document Size (Size of Exhibit 10.1 in bytes.)
Key Players & Entities
- Heron Therapeutics, Inc. (company) — Filer of the 8-K report
- 0000818033 (company) — CIK number for Heron Therapeutics, Inc.
- 2026-04-06 (date) — Filing date of the 8-K
- 2026-04-03 (date) — Period of report for the 8-K
FAQ
Who departed from Heron Therapeutics, Inc. as reported in Item 5.02?
The filing indicates the departure of a director, though the specific name is not detailed in the provided text.
What is the filing date of this 8-K report?
The 8-K report was filed on April 6, 2026.
What is the business address of Heron Therapeutics, Inc.?
The business address is 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121.
What are the main items covered in this 8-K filing?
The main items covered are Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits).
What is the CIK number for Heron Therapeutics, Inc.?
The CIK number for Heron Therapeutics, Inc. is 0000818033.
Filing Stats: 2,043 words · 8 min read · ~7 pages · Grade level 15.6 · Accepted 2026-04-06 08:30:11
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M
Filing Documents
- hrtx-20260403.htm (8-K) — 83KB
- hrtx-ex10_1.htm (EX-10.1) — 158KB
- hrtx-ex10_2.htm (EX-10.2) — 120KB
- hrtx-ex10_3.htm (EX-10.3) — 125KB
- hrtx-ex10_4.htm (EX-10.4) — 125KB
- 0001193125-26-142947.txt ( ) — 844KB
- hrtx-20260403.xsd (EX-101.SCH) — 49KB
- hrtx-20260403_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Amended and Restated Executive Employment Agreement, dated April 3, 2026, by and between Heron Therapeutics, Inc. and Craig Collard. 10.2 Amended and Restated Management Retention Agreement, dated April 3 , 2026, by and between Heron Therapeutics, Inc. and Bill Forbes . 10.3 Amended and Restated Management Retention Agreement, dated April 3 , 2026, by and between Heron Therapeutics, Inc. and Ira Duarte . 10.4 Amended and Restated Management Retention Agreement, dated April 3 , 2026, by and between Heron Therapeutics, Inc. and Mark Hensley. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: April 6, 2026 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer